Neem Biotech’s CEO, Dr. Graham Dixon, discussed developing a novel quorum sensing based treatment for wound and cystic fibrosis lung infections with Neal Howard of Health Professional Radio.

Interference with cell-to-cell signaling between bacteria can constrain the effect of their virulence factors. This could also be expected to reduce progression of AMR more broadly over the longer term. Listen to the interview here.